| Id: | acc1427 |
| Group: | 2sens |
| Protein: | eIF2a |
| Gene Symbol: | EIF2A |
| Protein Id: | Q9BY44 |
| Protein Name: | EIF2A_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser51 |
| Site Sequence: | CIFSKDGTLFAWGNGEKVNII |
| Disease Category: | Cancer |
| Disease: | Lung Cancer |
| Disease Subtype: | NSCLC |
| Disease Cellline: | A549 |
| Disease Info: | |
| Drug: | ZNF323A OV |
| Drug Info: | - |
| Effect: | modulate |
| Effect Info: | The drug induces protein phosphorylation and promotes tumor autophagy. |
| Note: | Non-conventional drugs |
| Score: | 3.0 |
| Pubmed(PMID): | 32576196 |
| Sentence Index: | 32576196_6-7 |
| Sentence: | "Thus, we further investigated the molecular regulation of ZNF322A, and found the inhibitory transcriptional regulation of ZNF322A on PIM3, which was able to phosphorylate IRS1 at serine1101 in order to manipulate glucose uptake via the PI3K/AKT/mTOR signaling pathway. Moreover, ZNF322A also affects the unfolded protein response by phosphorylation of HSP27S82 and eIF2aS51, and triggers autophagosome formation in lung cancer cells." |
Sequence & Structure:
MAPSTPLLTVRGSEGLYMVNGPPHFTESTVFPRESGKNCKVCIFSKDGTLFAWGNGEKVNIISVTNKGLLHSFDLLKAVCLEFSPKNTVLATWQPYTTSKDGTAGIPNLQLYDVKTGTCLKSFIQKKMQNWCPSWSEDETLCARNVNNEVHFFENNNFNTIANKLHLQKINDFVLSPGPQPYKVAVYVPGSKGAPSFVRLYQYPNFAGPHAALANKSFFKADKVTMLWNKKATAVLVIASTDVDKTGASYYGEQTLHYIATNGESAVVQLPKNGPIYDVVWNSSSTEFCAVYGFMPAKATIFNLKCDPVFDFGTGPRNAAYYSPHGHILVLAGFGNLRGQMEVWDVKNYKLISKPVASDSTYFAWCPDGEHILTATCAPRLRVNNGYKIWHYTGSILHKYDVPSNAELWQVSWQPFLDGIFPAKTITYQAVPSEVPNEEPKVATAYRPPALRNKPITNSKLHEEEPPQNMKPQSGNDKPLSKTALKNQRKHEAKKAAKQEARSDKSPDLAPTPAPQSTPRNTVSQSISGDPEIDKKIKNLKKKLKAIEQLKEQAATGKQLEKNQLEKIQKETALLQELEDLELGI
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| EIF2A-Ser481 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.254 | ||||
| COAD | -1.143 | ||||
| HGSC | 1.978 | ||||
| ccRCC | 0.421 | ||||
| GBM | -0.483 | ||||
| HNSC | 0.059 | ||||
| LUAD | -1.003 | ||||
| LUSC | -1.463 | ||||
| non_ccRCC | 1.047 | ||||
| PDAC | 0.224 | ||||
| UCEC | 0.108 | ||||
| EIF2A-Ser501 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.096 | ||||
| COAD | 0.065 | ||||
| HGSC | 2.656 | ||||
| ccRCC | -0.628 | ||||
| GBM | -0.4 | ||||
| HNSC | -0.228 | ||||
| LUAD | -0.676 | ||||
| LUSC | |||||
| non_ccRCC | -0.5 | ||||
| PDAC | 0.33 | ||||
| UCEC | -0.715 | ||||
| EIF2A-Ser503 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -1.132 | ||||
| HGSC | 1.288 | ||||
| ccRCC | -0.657 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | -0.842 | ||||
| non_ccRCC | |||||
| PDAC | 0.76 | ||||
| UCEC | 0.584 | ||||
| EIF2A-Thr487 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.905 | ||||
| HGSC | -0.168 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 1.073 | ||||
| EIF2AK1-Ser257 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | -0.294 | ||||
| HNSC | 1.036 | ||||
| LUAD | -0.623 | ||||
| LUSC | -1.165 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 1.046 | ||||
| EIF2AK1-Ser294 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 1.069 | ||||
| HNSC | -0.751 | ||||
| LUAD | |||||
| LUSC | -0.948 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.629 | ||||
| EIF2AK2-Ser167 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | 0.707 | ||||
| LUAD | -0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| EIF2AK2-Ser171 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | -0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.707 | ||||
| EIF2AK2-Ser33 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | 0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| EIF2AK2-Ser83 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.012 | ||||
| COAD | -0.018 | ||||
| HGSC | -0.58 | ||||
| ccRCC | |||||
| GBM | 1.525 | ||||
| HNSC | -1.437 | ||||
| LUAD | |||||
| LUSC | 0.522 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| EIF2AK2-Ser92 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | -1.155 | ||||
| ccRCC | 0.586 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.569 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| EIF2AK2-Ser93 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.953 | ||||
| HGSC | -1.041 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | 0.088 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| EIF2AK2-Thr170 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | 0.707 | ||||
| LUAD | -0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| EIF2AK3-Ser404 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.974 | ||||
| COAD | |||||
| HGSC | 1.579 | ||||
| ccRCC | 0.387 | ||||
| GBM | 0.07 | ||||
| HNSC | 0.184 | ||||
| LUAD | 0.272 | ||||
| LUSC | -0.245 | ||||
| non_ccRCC | 0.654 | ||||
| PDAC | -0.928 | ||||
| UCEC | |||||
| EIF2AK3-Ser537 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.088 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 1.35 | ||||
| LUSC | -1.063 | ||||
| non_ccRCC | |||||
| PDAC | -0.199 | ||||
| UCEC | |||||
| EIF2AK3-Ser564 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.021 | ||||
| COAD | -1.697 | ||||
| HGSC | 2.192 | ||||
| ccRCC | -0.232 | ||||
| GBM | -0.048 | ||||
| HNSC | -0.516 | ||||
| LUAD | 0.425 | ||||
| LUSC | 0.147 | ||||
| non_ccRCC | 0.49 | ||||
| PDAC | -0.74 | ||||
| UCEC | |||||
| EIF2AK3-Ser660 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.439 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.68 | ||||
| GBM | 0.12 | ||||
| HNSC | |||||
| LUAD | 1.11 | ||||
| LUSC | -0.471 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| EIF2AK3-Ser705 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.707 | ||||
| GBM | |||||
| HNSC | -0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| EIF2AK3-Ser941 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.741 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -1.96 | ||||
| GBM | 0.242 | ||||
| HNSC | 0.29 | ||||
| LUAD | |||||
| LUSC | 0.684 | ||||
| non_ccRCC | |||||
| PDAC | 0.004 | ||||
| UCEC | |||||
| EIF2AK3-Ser943 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.617 | ||||
| COAD | |||||
| HGSC | 2.07 | ||||
| ccRCC | 0.226 | ||||
| GBM | -0.082 | ||||
| HNSC | -0.331 | ||||
| LUAD | -0.373 | ||||
| LUSC | -0.018 | ||||
| non_ccRCC | 0.69 | ||||
| PDAC | -0.564 | ||||
| UCEC | |||||
| EIF2AK3-Ser945 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.953 | ||||
| HNSC | |||||
| LUAD | -1.041 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | 0.089 | ||||
| UCEC | |||||
| EIF2AK3-Ser964 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| EIF2AK3-Thr406 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.694 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | -1.146 | ||||
| LUAD | |||||
| LUSC | 0.452 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| EIF2AK4-Ser230 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.445 | ||||
| COAD | |||||
| HGSC | 2.732 | ||||
| ccRCC | -0.395 | ||||
| GBM | -0.115 | ||||
| HNSC | -0.278 | ||||
| LUAD | -0.804 | ||||
| LUSC | -0.508 | ||||
| non_ccRCC | 0.268 | ||||
| PDAC | -0.152 | ||||
| UCEC | -0.303 | ||||
| EIF2AK4-Ser572 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | 0.78 | ||||
| LUAD | |||||
| LUSC | -1.127 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.348 | ||||
| EIF2AK4-Ser770 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | -0.14 | ||||
| HNSC | -0.893 | ||||
| LUAD | -0.187 | ||||
| LUSC | -0.528 | ||||
| non_ccRCC | 2.1 | ||||
| PDAC | -0.621 | ||||
| UCEC | 0.269 | ||||
| EIF2AK4-Thr667 | |
|---|---|
| Cancer | Intensity |
| BRCA | -0.718 |
| COAD | -0.434 |
| HGSC | 2.669 |
| ccRCC | -0.092 |
| GBM | 0.155 |
| HNSC | -0.464 |
| LUAD | -0.237 |
| LUSC | -0.857 |
| non_ccRCC | 0.254 |
| PDAC | -0.857 |
| UCEC | 0.579 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 51 | U | Triple-negative breast cancer | Phosphorylation | 37834012 |
| S | 51 | U | Lung adenocarcinoma | Phosphorylation | 36226539 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
